Treatment Decisions for Stable Chronic Obstructive Pulmonary Disease in China: An Observational Cross-Sectional Survey Based on Multivariate Discrete Choice Modeling

Jiangyu Cui, Chunli Tang, Hongjia Li, Yumin Zhou, Shiyue LiInternational Journal of COPD 2025 · DOI

Abstract

Although most respiratory physicians follow guidelines for the choice of initial therapy for COPD, there are still irregularities in the use of triple therapy. A clinically relevant percentage of physicians, especially community physicians, selected ICS+LABA as the initial treatment choice. These practice irregularities should be the focus of future guidelines for promotion and education.

Introduction

Chronic Obstructive Pulmonary Disease (COPD) represents a significant public health challenge in China, with an estimated prevalence affecting nearly 100 million individuals. International standards, specifically the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, advocate for a structured approach to initial therapy, primarily utilizing long-acting bronchodilators (LAMA/LABA) and reserving inhaled corticosteroids (ICS) for specific high-risk phenotypes. However, clinical practice often diverges from these recommendations. Over-reliance on ICS-containing regimens, particularly triple therapy, poses risks such as increased pneumonia incidence and metabolic complications. This study aims to quantify these deviations among Chinese physicians and identify the clinical drivers behind non-adherent prescribing.

Methodology

This research utilized Multivariate Discrete Choice Modeling (DCM) to simulate clinical decision-making. Unlike traditional surveys, DCM presents physicians with specific patient scenarios to elicit revealed preferences. The study generated 872 simulated patient profiles based on key clinical characteristics: lung function (FEV1%pred), symptom severity (mMRC score), exacerbation history, peripheral blood eosinophil (EOS) counts, and comorbidities (asthma or pneumonia history).

A cohort of 109 physicians from various institutional levels—Community Health Care (CHC) centers, Secondary Hospitals (SH), and Tertiary Hospitals (TH)—evaluated these profiles to select the most appropriate initial treatment. This experimental design allowed for a direct comparison between physician choices and the 2023 GOLD guidelines.

Results and Analysis

The study revealed a systemic tendency toward overtreatment. Triple therapy (LAMA+LABA+ICS) emerged as the dominant prescription choice, accounting for 49.9% of all treatment selections. This preference persisted even in low-risk scenarios where guidelines recommend simpler bronchodilator regimens.

Treatment choices across GOLD groups A, B, and E by hospital level.

In GOLD Groups A and B (low-risk patients), approximately 60% of simulated patients were prescribed triple therapy. Conversely, LAMA monotherapy, a cornerstone of early-stage treatment, was significantly underutilized, representing only 4.9% of prescriptions. Furthermore, outdated regimens such as ICS/LABA combinations (no longer recommended as primary COPD starters) accounted for 14.3% of choices, with higher prevalence in community health settings.

Discussion: Clinical Drivers and Institutional Gaps

The analysis identified blood eosinophil (EOS) counts as a primary driver of treatment choice, though often applied inconsistently with guidelines. While high EOS counts (>300 cells/µL) appropriately increased ICS usage, low EOS counts (<100 cells/µL) frequently led physicians to omit ICS even when comorbid asthma made its use mandatory.

Impact of blood eosinophil (EOS) counts on treatment selection.

Institutional disparities were also evident. Physicians in tertiary hospitals demonstrated higher adherence to the latest GOLD guidelines. In contrast, community physicians often relied on older national guidelines or established habits, leading to higher rates of ICS/LABA and triple therapy overprescription in low-risk patients.

Limitations and Future Work

The study's findings are constrained by a relatively small sample size of 109 physicians and the inherent limitations of virtual patient simulations, which may not fully capture real-world nuances like patient cost-sensitivity. Future research should focus on longitudinal tracking of actual clinical outcomes to evaluate the impact of these prescribing patterns on patient health and to develop targeted educational interventions for primary care providers.

Summary updated

Abstract

Although most respiratory physicians follow guidelines for the choice of initial therapy for COPD, there are still irregularities in the use of triple therapy. A clinically relevant percentage of physicians, especially community physicians, selected ICS+LABA as the initial treatment choice. These practice irregularities should be the focus of future guidelines for promotion and education.
BibTeX
@article{cui2025treatment,
  author = {Jiangyu Cui and Chunli Tang and Hongjia Li and Yumin Zhou and Shiyue Li},
  title = {{Treatment Decisions for Stable Chronic Obstructive Pulmonary Disease in China: An Observational Cross-Sectional Survey Based on Multivariate Discrete Choice Modeling}},
  journal = {International Journal of COPD},
  year = {2025},
  doi = {10.2147/copd.s537500},
}
Figure